pd 169316 and activins

pd 169316 has been researched along with activins in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fu, Y; Nachtigal, MW; O'Connor, LM; Shepherd, TG	1

Other Studies

1 other study(ies) available for pd 169316 and activins

Article	Year
The p38 MAPK inhibitor, PD169316, inhibits transforming growth factor beta-induced Smad signaling in human ovarian cancer cells. Biochemical and biophysical research communications, 2003, Oct-17, Volume: 310, Issue:2 Topics: Activins; Cell Line, Tumor; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Imidazoles; Inhibin-beta Subunits; Mitogen-Activated Protein Kinases; Mutation; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Signal Transduction; Smad Proteins; Trans-Activators; Transforming Growth Factor beta; Transforming Growth Factor beta1	2003

Article

Year

The p38 MAPK inhibitor, PD169316, inhibits transforming growth factor beta-induced Smad signaling in human ovarian cancer cells.

Biochemical and biophysical research communications, 2003, Oct-17, Volume: 310, Issue:2

Topics: Activins; Cell Line, Tumor; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Imidazoles; Inhibin-beta Subunits; Mitogen-Activated Protein Kinases; Mutation; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Signal Transduction; Smad Proteins; Trans-Activators; Transforming Growth Factor beta; Transforming Growth Factor beta1

2003